2-(N-methyl-N-Boc)amino-5-iodopyridine | 1301256-18-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(N-methyl-N-Boc)amino-5-iodopyridine
• 英文别名: tert-butyl N-(5-iodopyridin-2-yl)-N-methylcarbamate
• CAS: 1301256-18-7
• 化学式: C₁₁H₁₅IN₂O₂
• 分子量: 334.157
• InChiKey: YLCGWNFAIVDDFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(N-methyl-N-Boc)amino-5-iodopyridine 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 pyridine-SO3 complex 、 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 生成 tert-butyl N-methyl-N-[5-(3-oxoprop-1-ynyl)pyridin-2-yl]carbamate
  参考文献：
  名称：

  NOVEL COMPOUND FOR IMAGING TAU PROTEIN ACCUMULATED IN THE BRAIN

  摘要：

  公开号：

  EP2767532B1
• 作为产物：
  描述：

  (5-碘2-吡啶基)氨基甲酸叔丁酯 、 碘甲烷 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-(N-methyl-N-Boc)amino-5-iodopyridine
  参考文献：
  名称：

  NOVEL COMPOUND FOR IMAGING TAU PROTEIN ACCUMULATED IN THE BRAIN

  摘要：

  公开号：

  EP2767532B1

文献信息

• Synthesis and evaluation of 6-(3-[18F]fluoro-2-hydroxypropyl)-substituted 2-pyridylbenzothiophenes and 2-pyridylbenzothiazoles as potential PET tracers for imaging Aβ plaques
  作者：Byoung Se Lee、So Young Chu、Hye Rim Kwon、Chansoo Park、Uthaiwan Sirion、Damian Brockschnieder、Thomas Dyrks、Seung Jun Oh、Jae Seung Kim、Dae Yoon Chi

  DOI：10.1016/j.bmc.2016.03.034

  日期：2016.5

  lipophilicities of the compounds. Intriguingly, (S)-configured PET tracers, (S)-[18F]1b and (S)-[18F]1c, exhibited a 2.8 and 4.0-fold faster brain washout rate at a peak/30 min in the mouse brain than the corresponding (R)-configured PET tracers despite there being no meaningful difference in binding affinities toward Aβ plaque. A further evaluation of (S)-[18F]1c with healthy rhesus monkeys also revealed excellent

  合成了3- [ 18 F]氟-2-羟丙基取代的化合物，并将其评估为新颖的18 F标记的PET示踪剂，用于在活脑中对Aβ斑块进行成像。所有化合物均对合成的Aβ1–42聚集体和/或阿尔茨海默氏病脑匀浆具有高结合亲和力。在正常小鼠的microPET研究中，被3- [ 18 F]氟-2-羟丙基取代的化合物通过降低化合物的亲脂性而导致快速的脑部冲洗。有趣的是，配置了（S）的PET示踪剂，（S）-[ 18 F] 1b和（S）-[ 18 F] 1c尽管在对Aβ斑块的结合亲和力上没有有意义的差异，但在小鼠脑中，在峰值/ 30分钟时，小鼠的脑部冲洗速度比相应的（R）配置PET示踪剂快了2.8和4.0倍。用健康的恒河猴对（S）-[ 18 F] 1c的进一步评估还显示，与额叶皮层的清除率极高，在30 / 60、90、90和120分钟的峰值时比率分别为7.0、16.0、30.0和49.0。 。这些结果表明，（S）-[
• (3-FLUORO-2-HYDROXY)PROPYL-FUNCTIONALIZED ARYL DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR THE DIAGNOSIS OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASES
  申请人：Chi Dae-Yoon

  公开号：US20120214994A1

  公开（公告）日：2012-08-23

  The present invention relates to (3-fluoro-2-hydroxy)propyl-functionalized aryl derivatives or to the pharmaceutically acceptable salt thereof, to a method for preparing same, and to a pharmaceutical composition containing same as active ingredients for the diagnosis or treatment of neurodegenerative brain diseases. The aryl derivatives of the present invention are (3-fluoro-2-hydroxy)propyl-functionalized to increase the polarity thereof, and therefore the drugs containing the aryl derivatives can easily permeate into the cerebrovascular membrane, thus increasing the effectiveness of the drugs. As the aryl derivatives of the present invention strongly bind to β-amyloid, the aryl derivatives, when labeled with radioisotope, can be used as a diagnostic agent for non-invasively diagnosing early Alzheimer's disease. Further, the aryl derivatives of the present invention bind to low molecular β-amyloid peptide conjugates to inhibit the generation of malignant high molecular β-amyloid plaque, and thus can be effectively used as a therapeutic agent for neurodegenerative brain diseases such as Alzheimer's disease.

  本发明涉及（3-氟-2-羟基）丙基官能化芳基衍生物或其药用可接受的盐，以及制备该衍生物的方法，以及含有该衍生物作为活性成分的药物组合物，用于诊断或治疗神经退行性脑疾病。本发明的芳基衍生物经（3-氟-2-羟基）丙基官能化以增加其极性，因此含有该芳基衍生物的药物可以轻松渗透到脑血管膜中，从而增加药物的有效性。由于本发明的芳基衍生物与β-淀粉样蛋白结合强，因此当该芳基衍生物标记放射性同位素时，可用作无创诊断早期阿尔茨海默病的诊断剂。此外，本发明的芳基衍生物与低分子量β-淀粉样肽结合以抑制恶性高分子量β-淀粉样斑块的生成，因此可以有效用作治疗阿尔茨海默病等神经退行性脑疾病的治疗剂。
• Novel Compounds for Imaging Tau Proteins That Accumulate In Brain
  申请人：National Institute of Radiological Sciences

  公开号：US20150239878A1

  公开（公告）日：2015-08-27

  The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R 1 and R 2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R 3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), R a is alkyl; R 4 and R 5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and [Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.

  本发明提供了一种化合物，其表示为以下式子（I），其药学上可接受的盐或其溶剂化物。其中：R1和R2各自独立地选择自氢，烷基，烯基，酰基和羟基烷基的群组；R3是氢或卤素；环A是苯环或吡啶环；环B选择自以下式子（i），（ii），（iii）和（iv）的群组：在式子（ii）中，Ra是烷基；R4和R5各自独立地选择自氢，羟基，烷氧基，卤代烷氧基，卤代羟基烷氧基和氨基烷基的群组；以及[公式3]表示双键或三键。以上化合物可用作成像在脑中积累的tau蛋白的分子探针。
• Compounds for imaging tau proteins that accumulate in the brain
  申请人：National Institutes for Quantum and Radiological Science and Technology

  公开号：US10604516B2

  公开（公告）日：2020-03-31

  The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and   [Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.

  本发明提供了由下式（I）代表的化合物、其药学上可接受的盐或其溶液。 其中 R1 和 R2 分别选自由氢、烷基、烯基、酰基和羟烷基组成的组； R3 是氢或卤素 环 A 是苯环或吡啶环； 环 B 选自下式 (i)、(ii)、(iii) 和 (iv) 所组成的组： 在式(ii)中，Ra 是烷基； R4 和 R5 分别选自由氢、羟基、烷氧基、卤代烷氧基、卤代羟基烷氧基和氨基烷基组成的组；以及 [式 3］ 代表双键或三键。上述化合物可用作分子探针，对大脑中积累的 tau 蛋白进行成像。
• Novel Compounds for Imaging Tau Proteins That Accumulate in the Brain
  申请人：National Institutes for Quantum and Radiological Science and Technology

  公开号：US20200262829A1

  公开（公告）日：2020-08-20

  The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R 1 and R 2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R 3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), R a is alkyl; R 4 and R 5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and [Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.